Delivery Order SPE2DB20D2104-SPE2DB22FR68X
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,948.36 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,083.53 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which enables the government to...
- This federal contract award is a delivery order valued at $2,352.00 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as...
- This federal contract award, valued at $2,314.05, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used to treat dry eye disease. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical....
- This federal contract award, valued at $6,549.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $23,225.40 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of March 6, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,235.24 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award, valued at $10,247.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a completion date of May 19, 2022. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.80 firm fixed-price delivery order is for the provision of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The contract has an ultimate completion date of March 17, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.80 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty medication used to treat dry eye disease. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FR68XDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,958.72 Delivery Order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This single-award IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. The contract has no set-aside designation, indicating open competition. In addition to the DLA contract, AmerisourceBergen also holds a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. These IDCs demonstrate the company's capacity to meet the diverse pharmaceutical needs of multiple government agencies on a large scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.0k | 1/31/22 |